Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02860546 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
A Phase 2 study, sponsored by Taiho Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT02860546 is a Phase 2 study that has completed, run by Taiho Oncology. The registered enrollment target is 18 participants.
The verdict
NCT02860546, a Phase 2 study, has completed, sponsored by Taiho Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
A Phase 2 Study with Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Participants with Microsatellite Stable Refractory Metastatic Colorectal Cancer
Interventions
- DRUG TAS-102
- DRUG nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-08-29 |
| Est. Completion | 2017-09-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02860546
The ClinicalTrials.gov registry entry for NCT02860546 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAS-102 is the first listed.
NCT02860546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02860546 about?
NCT02860546 is a clinical study titled "A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC". A Phase 2 Study with Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Participants with Microsatellite Stable Refractory Metastatic Colorectal Cancer
What is the current status of trial NCT02860546?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2016-08-29. Estimated completion is 2017-09-07.
What interventions are being tested in trial NCT02860546?
The interventions under investigation include: TAS-102 (DRUG), nivolumab (DRUG).
Who is sponsoring clinical trial NCT02860546?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.